7 results on '"Osto, Elena"'
Search Results
2. Long-term prognostic value of coronary flow reserve in psoriasis patients.
- Author
-
Piaserico, Stefano, Osto, Elena, Famoso, Giulia, Montisci, Roberta, De Michieli, Laura, Zanetti, Irene, Iliceto, Sabino, and Tona, Francesco
- Subjects
- *
PSORIASIS , *FLOW velocity , *PROGNOSIS , *BIOLOGICAL tags , *CORONARY circulation , *CARDIOVASCULAR diseases risk factors - Abstract
Psoriasis affects more than 3% of the general population and is associated with an increased risk of premature cardiovascular events and death. We assessed the prognostic role of coronary flow reserve (CFR) as a marker of coronary microvascular function in psoriasis patients asymptomatic for cardiovascular disease. We retrospectively analyzed 153 prospectively collected patients affected by psoriasis (123 male; age 36 ± 8 years) without cardiovascular disease. CFR in the left anterior descending coronary artery was detected by transthoracic Doppler echocardiography, at rest, and during adenosine infusion. CFR was the ratio of hyperemic to resting diastolic flow velocity. CFR ≤2.5 was the cut off to define the presence of coronary microvascular dysfunction (CMD). CMD was present in 23 patients (15%). Multivariable logistic regression analysis showed that CMD was associated with severe psoriasis (OR 3.1, p = 0.03), psoriatic arthritis (OR 2.9, p = 0.03), hypertension (OR 4.1, p = 0.009), and time elapsing since psoriasis diagnosis >6 years (OR 1.9, p = 0.03). Patients with CFR ≤2.5 had a lower survival free from events (p < 0.0001). In psoriasis patients, CFR may be a reliable prognostic marker for cardiovascular event-free survival and may help identify patients at higher risk of developing cardiovascular complications. Whether novel biologic therapies able to reduce skin disease will improve CMD and prognosis in these patients needs to be further studied, prospectively. Image 1 • This study analyzed the prognostic role of coronary flow reserve in psoriasis. • 153 psoriatic patients without cardiovascular disease were included. • Coronary microvascular dysfunction was present in 15% of patients. • Coronary flow reserve may be a prognostic marker for events-free survival. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
3. Treatment with tumor necrosis factor inhibitors restores coronary microvascular function in young patients with severe psoriasis.
- Author
-
Piaserico, Stefano, Osto, Elena, Famoso, Giulia, Zanetti, Irene, Gregori, Dario, Poretto, Anna, Iliceto, Sabino, Peserico, Andrea, and Tona, Francesco
- Subjects
- *
MICROCIRCULATION disorders , *TUMOR necrosis factors , *PSORIASIS , *TREATMENT effectiveness , *CORONARY circulation , *CARDIOVASCULAR diseases , *PATIENTS , *THERAPEUTICS - Abstract
Background and aims In patients with psoriasis, the chronic exposure to systemic inflammation can result in coronary microvascular dysfunction (CMD). In this self-controlled, prospective pilot study, we investigated whether a long-term treatment with TNF-α inhibitors effective against skin symptoms also improves coronary flow reserve in psoriasis patients (CFR). Methods We prospectively studied 37 consecutive psoriasis patients (31 male; age, 37.7 ± 8.5 years) without cardiovascular disease, before and after anti-TNF-α treatment. CFR in the left anterior descending coronary artery was detected by transthoracic Doppler echocardiography, at rest and during adenosine infusion. CFR was the ratio of hyperemic to resting diastolic flow velocity. A CFR ≤ 2.5 was considered a marker of CMD. Psoriasis was assessed by Psoriasis Area and Severity Index (PASI). High sensitive C-reactive protein (hs-CRP) and serum TNF-α were assessed. Results Overall, CFR increased from 2.2 ± 0.7 to 3.02 ± 0.8 ( p < 0.0001) after TNF-α inhibitors therapy. In patients with CMD, CFR increased from 1.88 ± 0.3 to 2.74 ± 0.5 ( p < 0.0001). In patients with normal CFR, CFR increased from 3.0 ± 0.5 to 3.7 ± 0.9 ( p = 0.08). CFR improvement after TNF-α inhibitors treatment was correlated with hs-CRP and TNF-α reduction ( p = 0.004 and p = 0.02, respectively), but not with change in PASI ( p = 0.5). Conclusions The present study demonstrates that TNF-α inhibitors treatment ameliorates CMD in patients with established psoriasis not responding to long-term conventional therapy. These findings suggest that a therapy specifically targeted against inflammation is able to positively affect coronary microvascular function. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
4. Impaired coronary flow reserve in young patients affected by severe psoriasis
- Author
-
Osto, Elena, Piaserico, Stefano, Maddalozzo, Anna, Forchetti, Giulia, Montisci, Roberta, Famoso, Giulia, Giovagnoni, Andrea, Peserico, Andrea, Iliceto, Sabino, and Tona, Francesco
- Subjects
- *
PSORIASIS , *BLOOD flow , *CORONARY disease , *CARDIOVASCULAR diseases , *FLOW velocity , *ECHOCARDIOGRAPHY - Abstract
Abstract: Objective: Our study aimed to evaluate the effects of psoriasis (Pso) on coronary microvascular function and whether there is a relationship between disease activity scores and coronary blood flow abnormalities. Methods: 56 young patients (pts) with Pso (42 M, aged 37±3 years) without clinical evidence of cardiovascular diseases, and 56 controls matched for age and gender were studied. Coronary flow velocity in the left anterior descending coronary artery was detected by transthoracic echocardiography at rest and during adenosine infusion. Coronary flow reserve (CFR) was the ratio of hyperaemic diastolic flow velocity (DFV) to resting DFV. A CFR≤2.5 was considered abnormal. Results: In pts with Pso, CFR was lower than in controls (3.2±0.9 vs. 3.7±0.7, p =0.02). CFR was abnormal (≤2.5) in 12 pts (22% vs. 0% controls, p <0.0001). Moreover, in pts with CFR≤2.5, Psoriasis Area Severity Index (PASI), a clinical score for Pso severity, was higher (11±6 vs. 7±3, p =0.006) compared to pts with CFR>2.5. At multivariable analysis PASI remained the only determinant of CFR≤2.5 (p =0.02). Conclusion: CFR in young pts with severe Pso without coronary disease is reduced suggesting a coronary microvascular dysfunction, independently related to the severity and extension of Pso. This early microvascular impairment might be hypothesized as the consequence of prolonged and sustained systemic inflammation and might explain the increased cardiovascular risk conferred by Pso. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
5. Coronary microvascular dysfunction may be related to IGF-1 in acromegalic patients and can be restored by therapy.
- Author
-
Tellatin, Sara, Maffei, Pietro, Osto, Elena, Dassie, Francesca, Famoso, Giulia, Montisci, Roberta, Martini, Chiara, Fallo, Francesco, Marra, Martina Perazzolo, Mioni, Roberto, Iliceto, Sabino, Vettor, Roberto, and Tona, Francesco
- Subjects
- *
MICROCIRCULATION disorders , *CARDIOVASCULAR diseases risk factors , *ACROMEGALY , *CORONARY circulation , *ATHEROSCLEROSIS , *PATIENTS , *DISEASE risk factors - Abstract
Background and aims Acromegaly increases the risk of cardiovascular mortality. Data on the cardiovascular risk in asymptomatic acromegaly are limited. In particular, data on coronary microvascular abnormalities are lacking. We assessed coronary flow reserve (CFR) as a marker of coronary microvascular function in asymptomatic acromegaly. Methods We studied 40 acromegalic patients (23 male, age 52 ± 11 years) without clinical evidence of cardiovascular disease, and 40 control subjects matched for age and sex. Coronary flow velocity in the left anterior descending coronary artery was detected by transthoracic Doppler echocardiography, at rest, and during adenosine infusion. CFR was the ratio of hyperaemic to resting diastolic flow velocity. Results CFR was lower in patients than in controls (2.9 ± 0.8 vs . 3.7 ± 0.6, p < 0.0001) and was abnormal (≤2.5) in 13 patients (32.5%) compared with any control subjects (0%) ( p < 0.0001). CFR was inversely related to insulin-like growth factor 1 (IGF-1) levels (r = −0.5, p < 0.004). In patients with CFR≤2.5, IGF-1 was higher (756 [381–898] μg/l versus 246 [186–484] μg/l, p < 0.007) whereas growth hormone (GH) levels were similar (6.3 [2.8–13.7] μg/l versus 5 [2.8–8.9] μg/l, p = 0.8). In multivariable linear regression analysis, IGF-1 was independently associated with CFR ( p < 0.0001). In multiple logistic regression analysis, IGF-1 independently increased the probability of CFR≤2.5 ( p = 0.009). In four patients with active disease (all with CFR<2.5), treatment with somatostatin analogues normalized CFR. However the other four patients with active disease were not responder. Conclusions Acromegalic patients have coronary microvascular dysfunction that may be restored by therapy with somatostatin analogues. IGF-1 independently correlates with the coronary microvascular impairment, suggesting the pivotal role of this hormone in explaining the increased cardiovascular risk in acromegaly. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
6. Long-term dietary supplementation with plant-derived omega-3 fatty acid improves outcome in experimental ischemic stroke.
- Author
-
Bonetti, Nicole R., Liberale, Luca, Akhmedov, Alexander, Pasterk, Lisa, Gobbato, Sara, Puspitasari, Yustina M., Vukolic, Ana, Saeedi Saravi, Seyed Soheil, Coester, Bernd, Horvath, Carla, Osto, Elena, Montecucco, Fabrizio, Lüscher, Thomas F., Beer, Jürg H., and Camici, Giovanni G.
- Subjects
- *
OMEGA-3 fatty acids , *ISCHEMIC stroke , *BLOOD-brain barrier , *DIETARY supplements , *OCCLUDINS , *ALPHA-linolenic acid , *CEREBRAL ischemia - Abstract
Early revascularization -the gold standard therapy for ischemic stroke- is often withheld in the elderly population due to high risk of complications. Thus, safe and effective preventive and therapeutic options are needed. The plant-derived omega-3-fatty-acid alpha-linolenic-acid (ALA) has emerged as a novel cardiovascular-protective agent. As of yet, little is known about its potential therapeutic effects on stroke. We hereby aimed to investigate the impact of a clinically relevant long-term dietary intervention with ALA on stroke outcome. Six month-old C57BL/6 wildtype males were either fed an ALA-rich (high ALA) or a control diet (low ALA) for 12 months. At 18 months, brain ischemia/reperfusion was induced by transient middle cerebral artery occlusion (tMCAO). Stroke size and neurological function were assessed. Functional blood-brain-barrier-(BBB) permeability and protein expression were assessed by immunohistochemistry. Baseline inflammatory markers were measured at 18 months. High ALA-fed animals displayed decreased circulating TNF-α levels and Neutrophil-to-Lymphocyte Ratios at 18 months. Stroke size and neurological dysfunction were significantly reduced in high ALA-fed animals. Coherently to the reduced stroke size, functional BBB integrity and occludin endothelial expression were maintained by high ALA supplementation. Additionally, ALA reduced endothelial activation and thus recruitment and activation of macrophages and resident microglia. Finally, high ALA diet reduced the expression of BBB-degrading and neurotoxic MMP-3 and MMP-9. We demonstrate the beneficial effects of a clinically relevant and feasible dietary intervention with a safe and readily available compound in the setting of stroke. The protective effects observed with ALA supplementation may relate to blunting of inflammation and might pave the way for novel stroke treatments. [Display omitted] • Long-term alpha-linolenic acid dietary supplementation improves stroke outcome. • Dietary alpha-linolenic acid reduces post-stroke blood-brain barrier impairment. • Alpha-linolenic acid reduces cerebral endothelial activation and inflammation. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.
- Author
-
Simic, Branko, Mocharla, Pavani, Crucet, Margot, Osto, Elena, Kratzer, Adelheid, Stivala, Simona, Kühnast, Susan, Speer, Thimoteus, Doycheva, Petia, Princen, Hans M., van der Hoorn, Jose W., Jukema, J. Wouter, Giral, Hector, Tailleux, Anne, Landmesser, Ulf, Staels, Bart, and Lüscher, Thomas F.
- Subjects
- *
CARDIOVASCULAR disease treatment , *CHOLESTERYL ester transfer protein , *HIGH density lipoproteins , *ENDOTHELIAL cells , *TRANSGENIC mice , *REACTIVE oxygen species , *CLINICAL trials - Abstract
Background and aims High-density lipoprotein cholesterol (HDL-C) is inversely related to cardiovascular risk. HDL-C raising ester transfer protein (CETP) inhibitors, are novel therapeutics. We studied the effects of CETP inhibitors anacetrapib and evacetrapib on triglycerides, cholesterol and lipoproteins, cholesterol efflux, paraoxonase activity (PON-1), reactive oxygen species (ROS), and endothelial function in E3L and E3L.CETP mice. Methods Triglycerides and cholesterol were measured at weeks 5, 14 and 21 in E3L.CETP mice on high cholesterol diet and treated with anacetrapib (3 mg/kg/day), evacetrapib (3 mg/kg/day) or placebo. Cholesterol efflux was assessed ex-vivo in mice treated with CETP inhibitors for 3 weeks on a normal chow diet. Endothelial function was analyzed at week 21 in isolated aortic rings, and serum lipoproteins assessed by fast-performance liquid chromatography. Results Anacetrapib and evacetrapib increased HDL-C levels (5- and 3.4-fold, resp.) and reduced triglycerides (−39% vs. placebo, p = 0.0174). Total cholesterol levels were reduced only in anacetrapib-treated mice (−32%, p = 0.0386). Cholesterol efflux and PON-1 activity (+45% and +35% vs. control, p < 0.005, resp.) were increased, while aortic ROS production was reduced with evacetrapib (−49% vs. control, p = 0.020). Anacetrapib, but not evacetrapib, impaired endothelium dependent vasorelaxation ( p < 0.05). In contrast, no such effects were observed in E3L mice for all parameters tested. Conclusions Notwithstanding a marked rise in HDL-C, evacetrapib did not improve endothelial function, while anacetrapib impaired it, suggesting that CETP inhibition does not provide vascular protection. Anacetrapib exerts unfavorable endothelial effects beyond CETP inhibition, which may explain the neutral results of large clinical trials in spite of increased HDL-C. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.